UC101 / Chengdu USino Techno - LARVOL DELTA

China‑based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101…has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) (flcube.com)

New trial • Hematological Malignancies

VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product (Businesswire) - "VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025....Incorporating an advanced design for gene editing, UC101 minimizes immunogenicity and demonstrates optimal efficacy while keeping adverse events under tighter control."

IND • Hematological Malignancies